The clinical-stage biotech had a big pipeline setback.
News & Analysis: Assembly Biosciences
An enthusiastic price for a secondary share offering lifted spirits and the stock.
Arrowhead Pharmaceuticals and Assembly Biosciences headed into an important industry meeting with rising share prices. Only one left the meeting with momentum intact.
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
Investors digesting a late-breaking data drop pushed up the stock.
The company reported promising updates for two important pipeline programs.
The potential is significant. Unfortunately, so is the hype.
Mid-stage clinical trial results weren't what some investors were looking for.
April's about to shower biopharma investors with important updates that could move these stocks.